DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Congress Asset Management Co.

Congress Asset Management Co. lessened its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 14.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,159,747 shares of the medical device company's stock after selling 197,194 shares during the period. Congress Asset Management Co. owned approximately 0.30% of DexCom worth $79,199,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of DXCM. Brighton Jones LLC increased its holdings in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after acquiring an additional 11,946 shares during the last quarter. Stratos Wealth Partners LTD. acquired a new position in DexCom during the fourth quarter worth $201,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in DexCom by 13.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 147,911 shares of the medical device company's stock worth $11,768,000 after purchasing an additional 17,650 shares during the last quarter. Consolidated Portfolio Review Corp purchased a new position in DexCom during the fourth quarter worth $220,000. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its position in DexCom by 15.4% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 47,263 shares of the medical device company's stock worth $3,676,000 after buying an additional 6,290 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Morgan Stanley lifted their price objective on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Canaccord Genuity Group boosted their price target on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Citigroup reiterated a "buy" rating and issued a $102.00 price target (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. The Goldman Sachs Group started coverage on DexCom in a report on Friday, May 30th. They issued a "buy" rating and a $104.00 price objective for the company. Finally, Wall Street Zen raised DexCom from a "hold" rating to a "buy" rating in a report on Friday. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $98.32.

DexCom Stock Up 1.1%

Shares of NASDAQ:DXCM traded up $0.93 during midday trading on Friday, hitting $86.67. 2,422,601 shares of the company's stock were exchanged, compared to its average volume of 4,340,357. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $118.80. The company has a market cap of $33.98 billion, a PE ratio of 60.61, a price-to-earnings-growth ratio of 2.30 and a beta of 1.46. The stock has a 50 day moving average price of $76.38 and a 200-day moving average price of $79.06. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 earnings per share. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares of the company's stock, valued at approximately $10,002,636.06. The trade was a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 10,000 shares of the company's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the sale, the executive vice president now directly owns 95,602 shares in the company, valued at approximately $8,057,336.56. The trade was a 9.47% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 83,110 shares of company stock valued at $6,103,505. Company insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.